Clinical and metabolic consequences of L-serine supplementation in hereditary sensory and autonomic neuropathy type 1C

Mari Auranen, Jussi Toppila, Saranya Suriyanarayanan, Museer A. Lone, Anders Paetau, Henna Tyynismaa, Thorsten Hornemann, Emil Ylikallio

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Hereditary sensory neuropathy type 1 (HSAN1) may be the first genetic neuropathy amenable to a specific mechanism-based treatment, as L-serine supplementation can be used to lower the neurotoxic levels of 1-deoxysphingolipids (1-deoxySL) that cause the neurodegeneration. The treatment is so far untested in HSAN1C caused by variants in the serine palmitoyl transferase subunit 2 (SPTLC2) gene. The aim of this study was to establish whether oral L-serine lowers 1-deoxySL in a patient with HSAN1C, to perform a dose escalation to find the minimal effective dose, and to assess the safety profile and global metabolic effects of the treatment. Our patient underwent a 52-wk treatment in which the L-serine dose was titrated up to 400 mg/kg/day. She was followed up by repeated clinical examination, nerve conduction testing, and skin biopsies to document effects on small nerve fibers. Serum was assayed for 1-deoxySL and metabolomics analysis of 111 metabolites. We found a robust lowering of 1-deoxySL, which correlated in a near-linear fashion with increased serum L-serine levels. Metabolomics analysis showed a modest elevation in glycine and a marked reduction in the level of cytosine, whereas most of the other assayed metabolites did not change. There were no direct side effects from the treatment, but the patient developed a transitory toe ulceration during the course of the study. The Charcot–Marie–Tooth neuropathy score increased by 1 point. We conclude that oral supplementation of L-serine decreases 1-deoxySL in HSAN1C without major global effects on metabolism. L-serine is therefore a potential treatment for HSAN1C.
Original languageEnglish
Article numbera002212
JournalCold Spring Harbor Molecular Case Studies
Volume3
Issue number6
Number of pages8
ISSN2373-2873
DOIs
Publication statusPublished - 21 Nov 2017
MoE publication typeA1 Journal article-refereed

Fields of Science

  • 3112 Neurosciences

Cite this

@article{c14cba40515944caa24097fe1393a5c6,
title = "Clinical and metabolic consequences of L-serine supplementation in hereditary sensory and autonomic neuropathy type 1C",
abstract = "Hereditary sensory neuropathy type 1 (HSAN1) may be the first genetic neuropathy amenable to a specific mechanism-based treatment, as L-serine supplementation can be used to lower the neurotoxic levels of 1-deoxysphingolipids (1-deoxySL) that cause the neurodegeneration. The treatment is so far untested in HSAN1C caused by variants in the serine palmitoyl transferase subunit 2 (SPTLC2) gene. The aim of this study was to establish whether oral L-serine lowers 1-deoxySL in a patient with HSAN1C, to perform a dose escalation to find the minimal effective dose, and to assess the safety profile and global metabolic effects of the treatment. Our patient underwent a 52-wk treatment in which the L-serine dose was titrated up to 400 mg/kg/day. She was followed up by repeated clinical examination, nerve conduction testing, and skin biopsies to document effects on small nerve fibers. Serum was assayed for 1-deoxySL and metabolomics analysis of 111 metabolites. We found a robust lowering of 1-deoxySL, which correlated in a near-linear fashion with increased serum L-serine levels. Metabolomics analysis showed a modest elevation in glycine and a marked reduction in the level of cytosine, whereas most of the other assayed metabolites did not change. There were no direct side effects from the treatment, but the patient developed a transitory toe ulceration during the course of the study. The Charcot–Marie–Tooth neuropathy score increased by 1 point. We conclude that oral supplementation of L-serine decreases 1-deoxySL in HSAN1C without major global effects on metabolism. L-serine is therefore a potential treatment for HSAN1C.",
keywords = "3112 Neurosciences",
author = "Mari Auranen and Jussi Toppila and Saranya Suriyanarayanan and Lone, {Museer A.} and Anders Paetau and Henna Tyynismaa and Thorsten Hornemann and Emil Ylikallio",
year = "2017",
month = "11",
day = "21",
doi = "10.1101/mcs.a002212",
language = "English",
volume = "3",
journal = "Cold Spring Harbor Molecular Case Studies",
issn = "2373-2873",
publisher = "Cold Spring Harbor Laboratory Press",
number = "6",

}

Clinical and metabolic consequences of L-serine supplementation in hereditary sensory and autonomic neuropathy type 1C. / Auranen, Mari; Toppila, Jussi; Suriyanarayanan, Saranya; Lone, Museer A.; Paetau, Anders; Tyynismaa, Henna; Hornemann, Thorsten; Ylikallio, Emil.

In: Cold Spring Harbor Molecular Case Studies, Vol. 3, No. 6, a002212, 21.11.2017.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Clinical and metabolic consequences of L-serine supplementation in hereditary sensory and autonomic neuropathy type 1C

AU - Auranen, Mari

AU - Toppila, Jussi

AU - Suriyanarayanan, Saranya

AU - Lone, Museer A.

AU - Paetau, Anders

AU - Tyynismaa, Henna

AU - Hornemann, Thorsten

AU - Ylikallio, Emil

PY - 2017/11/21

Y1 - 2017/11/21

N2 - Hereditary sensory neuropathy type 1 (HSAN1) may be the first genetic neuropathy amenable to a specific mechanism-based treatment, as L-serine supplementation can be used to lower the neurotoxic levels of 1-deoxysphingolipids (1-deoxySL) that cause the neurodegeneration. The treatment is so far untested in HSAN1C caused by variants in the serine palmitoyl transferase subunit 2 (SPTLC2) gene. The aim of this study was to establish whether oral L-serine lowers 1-deoxySL in a patient with HSAN1C, to perform a dose escalation to find the minimal effective dose, and to assess the safety profile and global metabolic effects of the treatment. Our patient underwent a 52-wk treatment in which the L-serine dose was titrated up to 400 mg/kg/day. She was followed up by repeated clinical examination, nerve conduction testing, and skin biopsies to document effects on small nerve fibers. Serum was assayed for 1-deoxySL and metabolomics analysis of 111 metabolites. We found a robust lowering of 1-deoxySL, which correlated in a near-linear fashion with increased serum L-serine levels. Metabolomics analysis showed a modest elevation in glycine and a marked reduction in the level of cytosine, whereas most of the other assayed metabolites did not change. There were no direct side effects from the treatment, but the patient developed a transitory toe ulceration during the course of the study. The Charcot–Marie–Tooth neuropathy score increased by 1 point. We conclude that oral supplementation of L-serine decreases 1-deoxySL in HSAN1C without major global effects on metabolism. L-serine is therefore a potential treatment for HSAN1C.

AB - Hereditary sensory neuropathy type 1 (HSAN1) may be the first genetic neuropathy amenable to a specific mechanism-based treatment, as L-serine supplementation can be used to lower the neurotoxic levels of 1-deoxysphingolipids (1-deoxySL) that cause the neurodegeneration. The treatment is so far untested in HSAN1C caused by variants in the serine palmitoyl transferase subunit 2 (SPTLC2) gene. The aim of this study was to establish whether oral L-serine lowers 1-deoxySL in a patient with HSAN1C, to perform a dose escalation to find the minimal effective dose, and to assess the safety profile and global metabolic effects of the treatment. Our patient underwent a 52-wk treatment in which the L-serine dose was titrated up to 400 mg/kg/day. She was followed up by repeated clinical examination, nerve conduction testing, and skin biopsies to document effects on small nerve fibers. Serum was assayed for 1-deoxySL and metabolomics analysis of 111 metabolites. We found a robust lowering of 1-deoxySL, which correlated in a near-linear fashion with increased serum L-serine levels. Metabolomics analysis showed a modest elevation in glycine and a marked reduction in the level of cytosine, whereas most of the other assayed metabolites did not change. There were no direct side effects from the treatment, but the patient developed a transitory toe ulceration during the course of the study. The Charcot–Marie–Tooth neuropathy score increased by 1 point. We conclude that oral supplementation of L-serine decreases 1-deoxySL in HSAN1C without major global effects on metabolism. L-serine is therefore a potential treatment for HSAN1C.

KW - 3112 Neurosciences

U2 - 10.1101/mcs.a002212

DO - 10.1101/mcs.a002212

M3 - Article

VL - 3

JO - Cold Spring Harbor Molecular Case Studies

JF - Cold Spring Harbor Molecular Case Studies

SN - 2373-2873

IS - 6

M1 - a002212

ER -